- Home
- SXTC vs BDRX Comparison
SXTC vs BDRX Comparison
Compare SXTC & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SXTC | BDRX |
|---|---|---|
| Founded | 2005 | 2000 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 1.8M |
| IPO Year | 2017 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SXTC | BDRX |
|---|---|---|
| Price | $1.36 | $0.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.5K | ★ 63.3K |
| Earning Date | 08-19-2019 | 09-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $0.65 |
| 52 Week High | $6.98 | $11.88 |
Technical Indicators
Market Signals| Indicator | SXTC | BDRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.46 | 27.25 |
| Support Level | $1.11 | N/A |
| Resistance Level | $1.58 | $1.29 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | -0.09 | 0.02 |
| Stochastic Oscillator | 0.00 | 12.11 |
Price Performance
Historical ComparisonAbout SXTC China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.